OKUR OnKure Therapeutics, Inc.
OnKure Therapeutics, Inc. (OKUR) is expected to report earnings on February 3, 2027, after the market close. The consensus earnings estimate is a loss of $0.30 per share, and the stock has had a Post-Earnings Announcement Drift (PEAD) of +11.0% since its last earnings release on November 4, 2026.
Sign in or subscribe to unlock sentiment, short interest, and technical indicators.
Whisperings™
About OnKure Therapeutics, Inc.
OnKure Inc. is a clinical-stage biopharmaceutical company. It focused on the discovery and development of precision medicines which target biologically validated drivers of cancers. The company is currently developing OKI-219. OnKure Inc., formerly known as Reneo Pharmaceuticals Inc., is based in IRVINE, Calif.
Sector
Healthcare
Industry
Biotechnology
Charts powered in part by Lightweight Charts™ by TradingView.